Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab in Atopic Dermatitis After Dupilumab Failure
NCT06773455Phase 4
Key facts
- Status
- Terminated
- Start
- Sep 2023
- Primary completion
- Jan 2026
- Countries
- 1
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Modality
- Monoclonal Antibodies
- Drugs
- tralokinumab
- Conditions
- atopic dermatitis (AD)
01
Overview
Phase 4, open-label, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by Psoriasis Treatment Center of Central New Jersey. Primary endpoint: Investigator's Global Assessment score of 0 or 1 at 16 weeks. Started Sep 2023; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Tralokinumab
Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks
03
Who it enrols
Adults with atopic dermatitis who had an inadequate response or intolerance to prior dupilumab treatment.
04
Endpoints
Primary
Investigator's Global Assessment score of 0 or 1
Beyond the preview
Go deeper on NCT06773455.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773455.